Credit: Unsplash/CC0 Public Domain A systematic review and network meta-analysis of 68 studies has found no clear evidence that any specific antipsychotic significantly improves cognitive function in patients with schizophrenia spectrum disorders compared to placebo. Cognitive deficits are a core component of schizophrenia spectrum disorders (SSDs), affecting memory, attention, and overall cognitive function, contributing significantly...
Author: RMG
Post
Melanoma: Genetically modified herpes virus may improve treatment
Researchers used a genetically modified herpes virus to treat advanced melanoma in a recent phase 2 clinical trial. Design by MNT; Photography by Smith Collection/Gado/Getty Images Advanced melanoma patients often face a risk of recurrence postsurgery. New approaches, like immunotherapies before surgery, could potentially help improve the body’s ability to fight cancer and improve patient...
Post
Scientists unravel how TET2 gene deficiency fuels development of acute myeloid leukemia
by City of Hope National Medical Center The return (i.e., homing) of leukemia stem cells (green) to the bone marrow microenvironment/niche (red) is substantially enhanced by low levels of TET2, at right, compared to the wild-type version of the gene. Credit: Jianjun Chen Laboratory/City of Hope Scientists at City of Hope, one of the largest cancer...
Post
Study finds increased MDS/leukemia risks for survivors of common lymphoid neoplasms
by Elana Gotkine Survivors of common lymphoid neoplasms (LNs) have increased risks for therapy-related myelodysplastic syndrome/acute myeloid leukemia (tMDS/AML), although risks have been lower in more recent years, according to a study published in the July issue of e ClinicalMedicine. Lindsay M. Morton, Ph.D., from the National Cancer Institute in Bethesda, Maryland, and colleagues identified...
Post
Topics for Research Papers – 9 Tips to help you write the best paper Another excellent topic for research papers is finding an angle. The process of selecting a topic for your research essay can be an issue, especially for students at all universities since you’re expected to write about something entirely novel, even if...
Post
FDA Warns AstraZeneca Over ‘Misleading Claims’ About COPD Drug
Lucy Hicks August 16, 2023 The US Food and Drug Administration (FDA) has issued a warning letter to AstraZeneca over the pharmaceutical company’s advertising of the efficacy of a treatment for chronic obstructive pulmonary disease (COPD). Promotional materials for the drug Breztri (budesonide/formoterol fumarate/glycopyrrolate inhaled) suggest that the drug has a positive effect on all-cause mortality for COPD patients, but the referenced clinical trial...
Post
Adderall shortages continue to cause issues as school starts
By Britney Heimuli Aug 17, 2023, 7:29 am MST Adderall XR capsules are displayed on Friday, Feb. 24, 2023. Jenny Kane, Associated Press As many students get ready to go back to school, the ongoing nationwide shortage of Adderall — a medication used to treat attention deficit hyperactivity disorder — might bring first-day jitters to some...
Post
Reviewing MAFLD opens new treatment pathways
FIRST HOSPITAL OF JILIN UNIVERSITY Non-alcoholic fatty liver disease (NAFLD) is a common condition that affects up to 30% of adults in the general population. It is characterized by the accumulation of fat in the liver. It is often associated with other conditions, such as obesity, type 2 diabetes, and metabolic syndrome. The new definition...
Post
Alarm as FDA fast-tracks first antipsychotic drug for agitation in dementia
by British Medical Journal Credit: Unsplash/CC0 Public Domain In trials, the antipsychotic drug brexpiprazole (Rexulti) failed to provide a clinically meaningful benefit and increased the risk of death. Yet the US Food and Drug Administration (FDA) has fast tracked its approval, making Rexulti the first antipsychotic for treating agitation in elderly patients with dementia. At a cost of...
Post
Q&A: Dermatologist discusses FDA approval for alopecia areata treatment
by Jim Shelton, Yale University Credit: Pixabay/CC0 Public Domain Just a year after the U.S. Food and Drug Administration (FDA) approved the first treatment for severe alopecia areata, the federal agency has approved a second treatment for the disfiguring skin disease—both the result of pioneering research by the same Yale dermatologist. On June 23, the FDA...